PMID- 35887799 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220731 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 14 DP - 2022 Jul 12 TI - Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa. LID - 10.3390/jcm11144037 [doi] LID - 4037 AB - Adalimumab is the only biologic agent approved for the treatment of moderate-to-severe hidradenitis suppurativa (HS) patients (i.e., with Hurley II or III), which is recommended in two different maintenance doses (i.e., 40 mg weekly or 80 mg every two weeks). We conducted a prospective multicentric study to measure outcomes related to the severity of disease and quality of life (QoL) of patients affected by moderate-to-severe HS, treated with adalimumab at a maintenance dosing of 40 mg or 80 mg. Assessments were performed at baseline (T0) and after 32 weeks of treatment (T32). We enrolled 85 moderate-to-severe HS Italian patients, 43 men (50.6%) and 42 women, aged between 16 and 62 years (median 31 years, interquartile range 24.4-43.8). Statistically significant improvements were observed for clinical status (with a mean reduction of 7.1 points for the International Hidradenitis Suppurativa Severity Score System (IHS4)), pain levels (3.1 mean decrease in VAS), and QoL (3.4 mean improvement in DLQI score). Patients with no comorbidities, and those with higher levels of perceived pain showed significantly greater improvement in QoL than their counterpart from T0 to T32. As for the proportion of patients who at follow-up reached the minimal clinical important difference (MCID) in QoL, significantly higher proportions of success were observed for age (patients in the 29-39 category), pain (patients with higher reported pain), and Hurley stage III. While both treatment regimen groups (i.e., 40 vs. 80 mg) improved significantly, no statistical differences were observed when comparing the two treatment dosages. FAU - Fania, Luca AU - Fania L AD - Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy. FAU - Giovanardi, Giulia AU - Giovanardi G AD - Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy. AD - Department of Dermatology, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy. FAU - Samela, Tonia AU - Samela T AUID- ORCID: 0000-0002-5588-5999 AD - Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy. FAU - Caposiena, Dante AU - Caposiena D AD - Department of Dermatology, University of Rome "Tor Vergata", 00133 Rome, Italy. FAU - Chiricozzi, Andrea AU - Chiricozzi A AD - Department of Dermatology, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy. FAU - Antonelli, Flaminia AU - Antonelli F AD - Department of Dermatology, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy. FAU - Saraceni, Pierluigi AU - Saraceni P AD - Istituto Dermatologico San Gallicano, IRCCS, 00144 Rome, Italy. FAU - Elia, Fulvia AU - Elia F AD - Istituto Dermatologico San Gallicano, IRCCS, 00144 Rome, Italy. FAU - Garcovich, Simone AU - Garcovich S AD - Department of Dermatology, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy. FAU - Ciccone, Davide AU - Ciccone D AD - Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy. FAU - Cannizzaro, Maria Vittoria AU - Cannizzaro MV AD - Department of Dermatology, University of Rome "Tor Vergata", 00133 Rome, Italy. FAU - Miraglia, Emanuele AU - Miraglia E AD - Dermatology Clinic Umberto I, Sapienza University of Rome, 00185 Rome, Italy. FAU - Iacovino, Chiara AU - Iacovino C AD - Dermatology Clinic Umberto I, Sapienza University of Rome, 00185 Rome, Italy. FAU - Giustini, Sandra AU - Giustini S AD - Dermatology Clinic Umberto I, Sapienza University of Rome, 00185 Rome, Italy. FAU - Skroza, Nevena AU - Skroza N AUID- ORCID: 0000-0003-4478-5404 AD - Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome-Polo Pontino, 00185 Rome, Italy. FAU - Mambrin, Alessandra AU - Mambrin A AD - Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome-Polo Pontino, 00185 Rome, Italy. FAU - Potenza, Concetta AU - Potenza C AD - Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome-Polo Pontino, 00185 Rome, Italy. FAU - Bianchi, Luca AU - Bianchi L AUID- ORCID: 0000-0001-8697-6896 AD - Department of Dermatology, University of Rome "Tor Vergata", 00133 Rome, Italy. FAU - Peris, Ketty AU - Peris K AUID- ORCID: 0000-0003-1957-6600 AD - Department of Dermatology, Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy. FAU - Abeni, Damiano AU - Abeni D AUID- ORCID: 0000-0002-0167-7617 AD - Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy. LA - eng PT - Journal Article DEP - 20220712 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9318217 OTO - NOTNLM OT - acne inversa OT - adalimumab OT - efficacy OT - hidradenitis suppurativa OT - pain OT - patient-reported outcome measures OT - quality of life OT - verneuil disease COIS- F.L., G.G., P.S., E.M. and A.M. has received thematically honoraria from AbbVie. Other authors declare no conflict of interest. EDAT- 2022/07/28 06:00 MHDA- 2022/07/28 06:01 PMCR- 2022/07/12 CRDT- 2022/07/27 01:27 PHST- 2022/05/04 00:00 [received] PHST- 2022/07/04 00:00 [revised] PHST- 2022/07/06 00:00 [accepted] PHST- 2022/07/27 01:27 [entrez] PHST- 2022/07/28 06:00 [pubmed] PHST- 2022/07/28 06:01 [medline] PHST- 2022/07/12 00:00 [pmc-release] AID - jcm11144037 [pii] AID - jcm-11-04037 [pii] AID - 10.3390/jcm11144037 [doi] PST - epublish SO - J Clin Med. 2022 Jul 12;11(14):4037. doi: 10.3390/jcm11144037.